Zobrazeno 1 - 10
of 101
pro vyhledávání: '"monoclonal antibodie"'
Autor:
Doubrovski V.A., Medvedeva M.F.
Publikováno v:
Саратовский научно-медицинский журнал, Vol 13, Iss 1, Pp 022-028 (2017)
The aim of the article is a comparison of resolution of the acousto-optical method for blood typing for two types of reagents: monoclonal antibodies and standard hemagglutinating sera. Materials and Methods: The influence of the concentrations of rea
Externí odkaz:
https://doaj.org/article/b4daf714deb74d49a51e4697e8e693d4
Autor:
Antonio Riccardo Buonomo, Nunzia Esposito, Isabella Di Filippo, Gabriele Saccone, Biagio Pinchera, Riccardo Scotto, Giuseppe Bifulco, Ivan Gentile
Publikováno v:
Expert Opinion on Drug Safety. 21:1137-1141
Autor:
Antonio Vitiello, Francesco Ferrara, Amogh M. Auti, Marina Di Domenico, Mariarosaria Boccellino
Publikováno v:
Journal of Internal Medicine. 292:81-90
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has spread worldwide, leading the World Health Organization (WHO) to declare a pandemic, on 11 March 2020. Variants of concern have appeared at regular intervals—Alpha, Beta, Gamma, Delta,
Autor:
Lucrezia Galassi, Martina Rossi, Pietro Lodeserto, Monia Lenzi, Francesca Borsetti, Manuela Voltattorni, Giovanna Farruggia, Paolo Blasi, Isabella Orienti
Publikováno v:
Pharmaceutics
Volume 15
Issue 2
Pages: 648
Volume 15
Issue 2
Pages: 648
Neuroblastoma cells highly express the disialoganglioside GD2, a tumor-associated carbohydrate antigen, which is also expressed in neurons, skin melanocytes, and peripheral nerve fibers. Immunotherapy with monoclonal anti-GD2 antibodies has a proven
Publikováno v:
Pharmaceuticals; Volume 16; Issue 5; Pages: 721
Background. Several drugs which are easy to administer in outpatient settings have been authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to prevent hospital admission and death, complementing COVID-19 vaccines. How
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00d0801da0523109dfd4f761bf2686ad
https://hdl.handle.net/11368/3044738
https://hdl.handle.net/11368/3044738
Autor:
Nevola, Riccardo, Feola, Giovanni, Ruocco, Rachele, Russo, Antonio, Villani, Angela, Fusco, Raffaele, De Pascalis, Stefania, Core, Micol Del, Cirigliano, Giovanna, Pisaturo, Mariantonietta, Loffredo, Giuseppe, Rinaldi, Luca, Marrone, Aldo, Starace, Mario, Sposito, Pellegrino De Lucia, Cozzolino, Domenico, Salvatore, Teresa, Lettieri, Miriam, Marfella, Raffaele, Sasso, Ferdinando Carlo, Coppola, Nicola, Adinolfi, Luigi Elio
Background: There is a scarcity of data on outcomes and predictors of therapeutic failure of mAbs in frail COVID-19 patients. Methods: Prospective study including consecutive COVID-19 outpatients referred by primary care physicians for mAbs treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3977::9d447e2b19f1e73e462b91597b91354e
https://hdl.handle.net/11591/494448
https://hdl.handle.net/11591/494448
Autor:
V. A. Misyurin, A. V. Misyurin, A. E. Misyurina, Yu. P. Finashutina, M. A. Baryshnikovа, O. S. Burova, S. K. Kravchenko
Publikováno v:
Онкогематология, Vol 10, Iss 4, Pp 56-59 (2015)
In present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad Company. Concentration of protein was measured using Bradford, s method. According to our res
Externí odkaz:
https://doaj.org/article/956f6b6bcae84a1494e866ac0b514d24
Autor:
Giulia Garzi, Francesco Cinetto, Davide Firinu, Giulia Di Napoli, Gianluca Lagnese, Alessandra Punziano, Patrick Bez, Bianca Laura Cinicola, Giulia Costanzo, Riccardo Scarpa, Federica Pulvirenti, Marcello Rattazzi, Giuseppe Spadaro, Isabella Quinti, Cinzia Milito
Publikováno v:
Frontiers in Immunology. 13
BackgroundSince the beginning of the COVID-19 pandemic, patients with Inborn Errors of Immunity have been infected by SARS-CoV-2 virus showing a spectrum of disease ranging from asymptomatic to severe COVID-19. A fair number of patients did not respo
Autor:
Antonio Reia, Riccardo Scotto, Emanuela Zappulo, Marcello Moccia, E. Pisano, Antonio Riccardo Buonomo, Ivan Gentile, Giulio Viceconte, V. Brescia Morra
Publikováno v:
Expert Opinion on Drug Safety. 20:925-936
Introduction: Disease modifying treatments are commonly used in the treatment of multiple sclerosis. As different opportunistic infections have been reported, concerns are also raised regarding the risk of invasive fungal infections. Areas covered: B
Autor:
Eugenio Baraldi, Giovanni Checcucci Lisi, Claudio Costantino, Jon H. Heinrichs, Paolo Manzoni, Matteo Riccò, Michelle Roberts, Natalya Vassilouthis
Publikováno v:
Human vaccinesimmunotherapeutics. 18(4)
Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizat